Granules India secures approval from SBTi for near-term, long-term, net-zero goals

27 Nov 2024 Evaluate

Granules India has received validation and approval from the Science Based Targets initiative (SBTi) for its near-term, long-term, and net-zero goals. These targets, aligned with the 1.5 degrees Celsius pathway, set Granules apart as one of the select Indian pharmaceutical companies with SBTi-validated targets under the initiative’s new guidelines. Granules’ goals are notable for their comprehensive scope and ambition.

Granules India has committed to achieving net-zero greenhouse gas (GHG) emissions across its value chain, including all subsidiaries, by FY2050. In the near term, the company targets a 42% reduction in absolute Scope 1 and 2 emissions and Scope 3 emissions by FY2030, using FY2023 as the baseline, alongside transitioning to 100% renewable electricity. These near-term and long-term targets are aligned with the 1.5 degrees Celsius pathway, emphasizing Granules' dedication to ambitious climate action and achieving net-zero well before FY2050.

Granules India is manufacturer and supplier of pharmaceutical products. Its products include active pharmaceutical ingredients (API) like tablets, caplets, rapid release, pharmaceutical, formulation intermediates (PFI) and Finished Dosages (FDs).


Granules India Share Price

534.55 0.10 (0.02%)
04-Dec-2024 13:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1796.90
Dr. Reddys Lab 1219.00
Cipla 1505.65
Lupin 2094.60
Zydus Lifesciences 970.15
View more..
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.